Rosen Quoted on Interchangeability and Biosimilar Guidances
January 7, 2015
BioWorld Today
Partner David Rosen was quoted in a BioWorld Today article, “FDA: Interchangeability, Other Guidances for Biosimilars in the Works,” on January 7, 2015. The article discussed possible FDA guidance changes on interchangeability, biosimilar draft guidance on labeling, statistical approaches for analyzing similarities in data, and implications of Biologic Price Competition and Innovation Act (BPCIA).
Rosen was quoted saying, “Some of the differences of opinion may be one of the reasons the guidances are a long time in coming. For instance, concerns about the potential market impact of naming and interchangeability guidelines could subject the drafts to the interagency review process.”
Related News
July 2, 2025
In the News
John Strom and Peter Tomasi Quoted on Shift in Environmental Policy
Foley & Lardner LLP attorneys John Strom and Peter Tomasi commented on changes to federal environmental rules in the Utility Dive article, "Federal agencies, including FERC and DOE, revoke environmental review rules."
June 30, 2025
In the News
Lynn Gandhi Assesses Midyear Takeaways from Major State and Local Tax Cases
Foley & Lardner LLP partner Lynn Gandhi is featured by Law360 for her takeaways on major state and local tax cases in the article, "Top State & Local Tax Cases Of 2025: Midyear Report."
June 27, 2025
In the News
Donald Schroeder Highlights FMCS Importance Amid Service's Uncertain Future
Foley & Lardner LLP partner Donald Schroeder described the Federal Mediation and Conciliation Services' (FMCS) importance in the Law360 article, "As Feds' Bargaining Mediator Ails, New Services Emerge."